increas
mortal
rate
patient
infect
major
resist
pathogen
follow
mrsa
mrsa
caus
almost
higher
mortal
compar
mssa
strain
accord
metaanalysi
cosgrov
et
al
mrsa
kill
american
peopl
everi
year
emphysema
hivaid
parkinson
diseas
homicid
combin
kleven
et
al
esblproduc
gramneg
bacilli
metaanalysi
show
crude
rr
significantli
higher
mortal
esblassoci
bacteremia
pool
rr
schwaber
et
al
carbapenemresist
kpneumonia
patient
carbapenemresist
kpneumonia
bacteremia
crude
mortal
rate
control
subject
borer
et
al
mortal
risk
ratio
patient
carbapenemresist
k
pneumonia
bacteremia
increas
mortal
morbid
resist
infect
due
treatment
failur
antibiot
therapi
associ
bacteri
fit
greater
sever
underli
ill
delay
initi
effect
therapi
lack
effect
therapi
friedman
et
al
due
mismatch
choic
empir
antibiot
vitro
suscept
test
result
administr
effect
antibiot
delay
case
antibioticresist
ecoli
kpneumonia
infect
compar
suscept
strain
hour
vs
hour
lautenbach
et
al
also
patient
infect
resist
strain
frequent
associ
sever
underli
ill
requir
longer
hospit
exampl
patient
cre
infect
like
transplant
recipi
requir
mechan
ventil
prolong
hospit
icu
stay
use
central
venou
cathet
borer
et
al
patient
infect
resist
strain
like
develop
complic
longterm
sequela
exampl
mrsa
infect
caus
higher
incid
complic
compar
mssa
infect
frequent
complic
progress
local
infect
rr
pneumonia
rr
cecchini
et
al
amr
emerg
hospit
resist
pathogen
caus
addit
case
bacteri
infect
affect
patient
emerg
amr
major
human
pathogen
also
affect
safeti
efficaci
surgic
procedur
cancer
chemotherapi
organ
transplant
intens
care
therefor
amr
infecti
diseas
issu
rather
issu
surgeri
cancer
care
organ
transplant
whole
health
system
amr
also
neg
affect
daili
hospit
activ
total
closur
affect
ward
unit
cancel
elect
surgeri
econom
impact
amr
difficult
quantifi
consist
direct
cost
associ
use
expens
antibiot
special
equip
longer
hospit
stay
isol
procedur
etc
indirect
cost
mainli
due
loss
product
patient
accord
world
bank
report
estim
amr
impact
global
gdp
world
bank
optimist
lowamr
scenario
global
econom
output
project
lower
trillion
lower
base
case
pessimist
highamr
impact
scenario
global
econom
output
would
lower
trillion
lower
base
case
mean
highamr
scenario
econom
damag
greater
global
financi
crisi
caus
drop
global
gdp
econom
impact
amr
differ
countri
differ
econom
level
lowincom
lower
middleincom
countri
would
greater
impact
econom
loss
loss
gdp
due
amr
compar
highincom
countri
loss
gdp
particularli
highamr
scenario
global
economi
neg
affect
amr
variou
aspect
intern
trade
livestock
product
healthcar
expenditur
volum
global
real
export
may
decreas
lowamr
scenario
highamr
scenario
highamr
scenario
healthcar
expenditur
would
higher
baselin
valu
lowincom
countri
higher
middleincom
countri
higher
highincom
countri
addit
expenditur
would
trillion
annual
highamr
scenario
us
cdc
estim
cost
amr
total
billion
per
year
billion
excess
direct
healthcar
cost
billion
indirect
societ
cost
due
loss
product
cdc
europ
overal
econom
burden
amr
estim
least
billion
euro
direct
cost
indirect
cost
ecdcemea
data
econom
impact
amr
major
pathogen
show
healthcar
cost
significantli
increas
treatment
infect
caus
antibioticresist
strain
maragaki
et
al
mrsa
bacteremia
us
mrsa
surgic
site
infect
us
vre
infect
us
esbl
kpcproduc
ecoli
klebsiella
infect
increas
amr
obvious
one
seriou
urgent
issu
devast
impact
clinic
medicin
econom
growth
societ
system
function
leader
declar
announc
juli
also
underlin
import
combat
amr
intern
collabor
effect
robust
implement
global
action
plan
combat
amr
appropri
evalu
impact
amr
perform
particularli
develop
world
would
greater
damag
due
amr
school
public
health
univers
hong
kong
china
develop
largescal
product
widespread
use
antimicrobi
drug
twentieth
centuri
turn
point
human
histori
result
dramat
improv
medic
care
reduct
death
time
howev
rise
level
antimicrobi
resist
amr
among
wide
rang
pathogen
place
gain
risk
lost
reduc
amr
toplevel
global
public
health
prioriti
principl
major
highlevel
goal
consist
optim
use
drug
health
agricultur
minim
environment
contamin
sustain
develop
new
class
antimicrobi
drug
medicin
make
afford
access
need
much
effect
applic
infect
control
prevent
principl
decad
technic
solut
primari
approach
use
address
amr
recent
fao
oie
combin
likemin
champion
embark
upon
polit
broader
one
health
approach
increas
awar
engag
beyond
scientif
medic
group
chang
basi
global
action
amr
high
level
meet
amr
held
un
gener
assembl
attent
amr
group
result
instrument
broaden
awar
attent
paid
amr
critic
adopt
concret
focus
activ
consolid
build
upon
gain
fundament
build
block
propos
discuss
murdoch
univers
australia
methicillinresist
staphylococcu
aureu
mrsa
initi
healthcar
associ
pathogen
limit
distinct
lineag
often
associ
multidrug
resist
howev
late
mrsa
began
emerg
commun
begin
mostli
confin
close
commun
ie
australian
aborigin
around
late
communityassoci
mrsa
camrsa
emerg
worldwid
gener
popul
camrsa
clone
evolv
independ
hamrsa
clone
typic
possess
type
iv
v
sccmec
element
non
multidrug
resist
posit
panton
valentin
leucocidin
pvl
toxin
whilst
region
mani
uniqu
camrsa
clone
emerg
clone
predomin
within
region
even
fewer
clone
global
distribut
reason
variat
preval
domin
camrsa
clone
differ
geograph
nich
remain
unclear
although
epidemiolog
camrsa
vari
consider
four
major
global
camrsa
clone
describ
south
west
pacif
clone
consid
pandem
european
clone
predomin
europ
africa
middl
east
taiwanasia
pacif
clone
asia
howev
use
whole
genom
sequenc
analysi
least
two
clone
differ
clade
evolv
independ
clonal
complex
nine
phylogenet
clade
least
eight
independ
event
methicillinresist
acquisit
identifi
subsequ
hypothesis
evolv
healthcareassoci
clone
histor
camrsa
western
australia
pvlposit
mssa
clone
trinidad
tobago
western
africa
like
pvlposit
mssa
circul
within
usa
ancestor
clade
emerg
central
europ
th
centuri
export
north
america
earli
th
centuri
north
america
clone
progress
acquir
characterist
genet
specif
diversifi
spread
global
includ
africa
within
clade
two
close
relat
clone
recognis
primarili
isol
north
america
spa
lukspvlukfpv
acm
posit
msramedi
macrolid
resist
gene
latin
american
variant
primarili
isol
south
america
spa
lukspvlukfpv
acm
neg
tetk
copper
mercuri
resist
gene
similarli
mrsa
also
singl
clone
consist
two
major
clade
one
origin
usa
east
asia
furthermor
two
distinct
subclad
within
east
asia
clade
identifi
pvlneg
asia
pacif
clone
multiresist
pvl
posit
taiwan
clone
possess
two
distinct
ccrc
gene
recent
three
newli
describ
pvlposit
camrsa
clone
report
multipl
countri
queensland
camrsa
australia
bengal
bay
indian
subcontin
first
report
india
genet
distinct
healthcar
associ
acquir
differ
sccmec
type
sub
type
concern
multiresist
hypervirul
camrsa
recent
associ
nosocomi
transmiss
coemerg
multipl
camrsa
lineag
risen
independ
part
world
strike
date
singl
genet
epidemiolog
factor
identifi
account
extraordinari
success
genet
distinct
camrsa
clone
time
camrsa
clone
replac
hamrsa
clone
signific
clinic
public
health
implic
along
way
becom
increas
antibiot
resist
make
distinct
hamrsa
camrsa
blur
antimicrobi
treatment
difficult
methicillinresist
staphylococcu
aureu
mrsa
major
caus
healthcareassoci
infect
signific
morbid
mortal
becom
one
import
nosocomi
pathogen
mani
countri
worldwid
sinc
particular
sever
mrsa
clone
success
spread
caus
infect
hospit
patient
preval
rate
mrsa
aureu
isol
hospit
patient
becom
high
enough
spread
commun
interestingli
past
two
decad
emerg
communityassoci
ca
mrsa
clone
greatli
affect
global
epidemiolog
aureu
infect
circul
camrsa
clone
vari
accord
region
includ
mostli
belong
sccmec
type
iv
v
result
proport
mrsa
communityacquir
aureu
infect
significantli
increas
mani
countri
furthermor
mani
report
shown
camrsa
clone
replac
tradit
hospitalendem
mrsa
clone
influx
domin
camrsa
clone
hospit
make
search
destroy
polici
contribut
maintain
low
mrsa
rate
countri
difficult
maintain
addit
concern
healthcareassoci
infect
surgic
site
infect
caus
camrsa
may
increas
talk
updat
camrsa
epidemiolog
healthcareassoci
infect
concern
infect
prevent
control
discuss
newli
emerg
middl
east
respiratori
syndrom
coronaviru
merscov
caus
sever
respiratori
infect
high
mortal
rate
global
threat
due
continu
outbreak
arabian
peninsula
intern
spread
infect
travel
sinc
may
juli
larg
outbreak
initi
infect
travel
arabian
peninsula
swept
south
korea
result
confirm
case
death
casefat
rate
show
rapid
emerg
spread
mutant
merscov
reduc
affin
human
receptor
korean
outbreak
isol
thirteen
new
viral
genom
fourteen
infect
patient
treat
hospit
found
twelv
possess
point
mutat
receptorbind
domain
rbd
viral
spike
protein
also
analyz
clinic
data
specimen
fourteen
mer
patient
treat
hospit
collect
repres
wide
spectrum
diseas
sever
rang
mild
febril
ill
fatal
pneumonia
compar
kinet
analys
reveal
high
viral
load
weak
antibodi
respons
lymphopenia
accompani
thrombocytopenia
associ
diseas
mortal
wherea
persist
gradual
increas
lymphocyt
respons
might
requir
effect
immun
merscov
infect
correl
virolog
immunolog
respons
diseas
sever
mortal
well
respons
current
antivir
therapi
may
prognost
signific
earli
phase
mer
sever
fever
thrombocytopenia
syndrom
sft
discov
infecti
diseas
caus
novel
bunyaviru
china
n
engl
j
med
caus
agent
sft
name
sft
viru
sftsv
tickborn
viru
belong
famili
buniyavirida
genu
phleboviru
viru
infect
caus
gener
infect
high
case
fatal
rate
late
discov
sft
also
endem
japan
takahashi
et
al
jid
sft
endem
china
south
korea
japan
sinc
discoveri
sft
endem
japan
januari
approxim
patient
sft
report
nation
institut
infecti
diseas
case
fatal
patient
age
pathophysiolog
sft
studi
patholog
examin
sft
patient
die
patholog
studi
sft
sftsv
present
lymph
node
tissu
two
patholog
type
sftsvposit
lymph
nodeloc
type
sftsvposit
lymph
nodegener
type
patient
bone
marrow
aspir
test
perform
show
hemophagocyt
syndrom
indic
cytokin
storm
play
import
role
pathogenesi
sft
fatal
sft
patient
show
symptom
hemorrhag
deterior
conscious
one
patient
show
symptom
bloodi
vomit
real
time
imag
stomach
endoscop
examin
reveal
presenc
ulcer
lesion
whooz
hemorrhag
kaneyuki
et
al
jjid
pathophysiolog
featur
behind
high
case
fatal
rate
sft
hemophagocytosi
hemorrhag
tendenc
due
thrombocytopenia
dissemin
intravascular
coagul
ulcer
lesion
appear
gastrointestin
tract
multiorgan
failur
efficaci
antivir
agent
favipiravir
develop
dr
furuta
colleagu
toyama
chemic
co
ltd
japan
treatment
sft
evalu
use
mice
lack
type
interferon
alpha
receptor
ifnar
tani
h
et
al
msphere
favipiravir
inhibit
replic
sftsv
vero
cell
log
unit
inhibitori
concentr
ic
ic
respect
intraperiton
oral
administr
favipiravir
day
mice
infect
lethal
sftsv
significantli
improv
surviv
rate
surviv
without
caus
bodi
weight
loss
reduc
viral
load
serum
although
ribavirin
also
inhibit
sftsv
replic
quit
less
effect
favipiravir
vitro
vivo
timeofdrugaddit
studi
reveal
therapeut
favipiravir
treatment
sftsv
infect
mice
effect
result
suggest
favipiravir
might
promis
candid
antivir
drug
sft
studi
suggest
favipiravir
candid
drug
treatment
sft
present
present
overview
epidemiolog
pathophysiolog
evalu
patholog
autopsi
develop
strategi
antivir
drug
therapi
sft
diseas
sft
continu
endem
china
korea
japan
futur
escap
risk
infect
sftsv
hand
potenti
favipiravir
therapeut
effect
treatment
sft
safe
efficaci
vaccin
sft
develop
furthermor
discuss
issu
address
reduc
sft
diseas
burden
challeng
pose
infecti
diseas
st
centuri
forev
grow
complex
numer
magic
bullet
simpl
solut
employ
battl
array
pathogen
everi
day
attack
human
anim
plant
much
mitig
chang
landscap
infecti
diseas
threat
present
expand
upon
dr
osterholm
previou
plenari
session
lectur
go
detail
describ
major
step
must
take
tip
balanc
grow
threat
infecti
diseas
abil
anticip
threat
prevent
control
result
increas
morbid
mortal
polymyxin
colistin
polymyxin
e
polymyxin
b
effect
antibiot
multidrugresist
mdr
gramneg
current
consid
lastlin
drug
treat
sever
bacteri
infect
polymyxin
resist
among
gramneg
increas
gradual
last
year
knowledg
multifacet
resist
mechan
expand
typic
colistin
resist
due
chromosom
mediat
modul
twocompon
regulatori
system
lead
modif
lipid
result
reduc
affin
polymyxin
clone
polymyxinresist
gramneg
spread
hospit
significantli
affect
use
polymyxin
resist
gene
gener
transmiss
bacteria
dissemin
wide
howev
newli
discov
plasmidmedi
polymyxin
resist
gene
detect
mani
countri
differ
geograph
region
world
sinc
first
report
therefor
seem
inevit
plasmidmedi
transfer
polymyxin
resist
serious
reduc
lifespan
polymyxin
backbon
regimen
infect
due
mdr
gramneg
review
provid
updat
epidemiolog
mechan
polymyxin
resist
among
differ
commonli
encount
mdr
gramneg
bacilli
unresolv
question
respect
polymyxin
resist
also
discuss
one
remain
option
infecti
diseas
caus
multipledrug
resist
gramneg
bacilli
colistin
accordingli
emerg
mobil
colistin
resist
phosphoethanolamin
transferas
becam
death
threat
public
health
variou
enterobacteriacea
carri
human
be
anim
environ
report
asia
europ
africa
north
south
america
south
korea
retrospect
screen
animalori
escherichia
coli
strain
posit
isol
identifi
evalu
clinic
strain
total
enterobacteriacea
isol
collect
screen
final
three
strain
two
escherichia
coli
belong
either
one
enterobact
aerogen
harbor
gene
identifi
possess
colistin
mic
gml
e
coli
strain
gml
e
aerogen
bla
gene
extendedspectrum
betalactamas
cocarri
e
aerogen
extra
plasmid
carri
bla
bla
bla
coharbor
e
coli
strain
one
e
coli
strain
produc
complet
conjug
machineri
present
best
effici
plasmid
transfer
e
aerogen
truncat
prepilin
peptidas
pilu
result
complet
loss
conjug
activ
plasmid
e
coli
transfer
effici
e
coli
recipi
compar
k
pneumonia
enterobact
cloaca
probabl
due
speciesspecif
allow
rearrang
shufflon
previous
identifi
e
coli
strain
animalorigin
south
korea
also
possess
nonselftransfer
e
aerogen
close
associ
selftransfer
e
coli
strain
alik
plasmid
carri
gene
bacteri
host
harbor
plasmid
come
anim
previou
report
illustr
better
stewardship
proper
usag
antimicrobi
well
collabor
surveil
studi
concept
onehealth
need
use
clinic
practic
yohei
doi
md
phd
univers
pittsburgh
usa
colistin
resist
enterobacteriacea
due
plasmidmedi
mcr
gene
drawn
much
attent
threat
colistin
resist
impact
patient
care
current
exist
extens
drugresist
xdr
bacteria
acquir
colistin
resist
chromosom
mutat
speci
klebsiella
pneumonia
pseudomona
aeruginosa
acinetobact
baumannii
unlik
mcr
mechan
readili
spread
horizont
via
plasmid
colistin
resist
xdr
speci
usual
aris
select
pressur
patient
upon
treatment
colistin
though
outbreak
also
report
occas
develop
colistin
resist
strain
mean
even
remain
activ
agent
howev
patient
affect
bacteria
medic
complex
heterogen
difficult
enrol
clinic
trial
mani
reason
consequ
clinic
data
associ
colistin
resist
antimicrobi
therapi
given
patient
outcom
scarc
retrospect
natur
part
k
pneumonia
limit
data
suggest
mortal
infect
colistinresist
strain
may
lower
treat
gentamicincontain
regimen
without
gentamicin
approach
applic
infect
strain
suscept
agent
fortun
approv
ceftazidimeavibactam
amelior
concern
colistin
resist
k
pneumonia
least
time
therapi
ceftazidimeavibactam
appear
improv
clinic
outcom
infect
patient
treat
colistinbas
regimen
interestingli
gastrointestin
decolon
gentamicin
may
reduc
infect
mortal
known
colon
colistinresist
k
pneumonia
recent
spread
mcr
gene
human
bring
question
longterm
viabil
approach
even
less
clinic
data
regard
treatment
infect
caus
colistinresist
p
aeruginosa
baumannii
vitro
data
variabl
support
colistinbas
combin
partner
agent
includ
carbapenem
rifampicin
fosfomycin
even
gramposit
agent
like
vancomycin
case
baumannii
without
accompani
robust
clinic
data
sever
novel
agent
activ
colistinresist
strain
latestag
clinic
develop
includ
novel
betalactambetalactamas
inhibitor
combin
siderophor
cephalosporin
aminoglycosid
tetracyclin
target
carbapenemresist
enterobacteriacea
also
activ
p
aeruginosa
baumannii
new
agent
bound
chang
paradigm
treatment
infect
caus
colistinresist
gramneg
uncertainti
still
like
remain
includ
agent
use
optim
dose
maxim
efficaci
minim
toxic
well
potenti
develop
resist
whether
use
one
agent
would
still
need
analyt
health
usa
unit
state
telehealth
repres
rapid
conveni
costeffect
solut
nonlif
threaten
condit
includ
acut
respiratori
infect
urinari
tract
infect
uti
sexual
transmit
infect
sti
billion
outpati
brick
mortar
visit
occur
annual
us
estim
one
third
visit
million
handl
telehealth
furthermor
one
third
subgroup
consult
million
relat
infecti
diseas
caus
recent
provis
diagnost
test
conjunct
telemedicin
physician
consult
difficult
due
divers
geoloc
patient
physician
test
laboratori
exampl
virtual
world
telehealth
patient
locat
california
physician
licens
practic
california
locat
three
time
zone
away
new
york
linkag
physician
patient
easili
accomplish
electron
mean
eg
video
conferenc
phone
call
text
messag
howev
obtain
specimen
patient
transport
specimen
appropri
test
laboratori
challeng
telemedicin
consult
perform
without
diagnost
test
empir
treatment
provid
approach
especi
acut
respiratori
infect
could
result
overus
underus
antibiot
lectur
describ
new
approach
diagnost
test
infecti
diseas
telehealth
ecosystem
includ
descript
infrastructur
requir
requir
andor
recent
develop
accommod
specimen
acquisit
test
aggreg
uber
izat
physician
laboratori
patient
servic
center
provis
round
clock
mobil
collect
inhom
collect
servic
selfcollect
selftest
also
costsav
approach
contrast
tradit
brick
mortar
approach
discuss
rapid
molecular
point
care
test
instrument
avail
accur
complet
confirm
test
requir
test
group
streptococcu
throat
swab
specimen
influenza
rsv
nasopharyng
swab
specimen
futur
test
capabl
includ
sexual
transmit
diseas
like
neisseria
gonorrhoea
chlamydia
trachomati
human
papilloma
viru
hpv
new
devic
accommod
next
inflect
point
virtual
medicin
point
patient
test
includ
test
patient
home
world
bank
estim
epidem
cost
trillion
dollar
st
centuryroughli
billion
per
year
billion
cost
ebola
epidem
econom
impact
countri
least
afford
howev
impact
ebola
famili
social
custom
health
infrastructur
long
term
consequ
addit
fund
epidem
diseas
wax
wane
passag
epidem
consequ
longer
term
prevent
solut
vaccin
littl
mean
progress
sever
nation
charit
foundat
launch
new
enterpris
known
cepi
coalit
epidem
prepared
innov
cepi
fund
develop
vaccin
candid
diseas
epidem
potenti
initi
candid
mer
nipah
lassa
fever
review
product
develop
activ
diseas
also
detail
attempt
intern
organ
tri
develop
framework
around
respons
public
health
emerg
intern
concern
carbapenemas
kpc
ndm
divers
enzym
divers
clone
david
livermor
norwich
medic
school
univers
east
anglia
norwich
uk
carbapenemaseproduc
enterobacteriacea
present
grow
problem
predomin
enzym
member
kpc
ndm
imp
vim
famili
rarer
type
includ
imi
sme
fri
enzym
also
member
ge
famili
kpc
imi
sme
fri
ge
enzym
belong
class
ndm
imp
vim
class
b
metallo
carbapenemas
whilst
rel
eg
belong
class
divers
enzym
reflect
divers
properti
kpc
carbapenemas
hydrolys
wide
avail
inhibit
avibactam
vaborbactam
contrast
metallo
type
evad
avibactam
vaborbactam
attack
except
monobactam
often
compromis
coproduc
esbl
ampc
enzym
inhibit
avibactam
vaborbactam
littl
activ
oxyiminocephalosporin
often
accompani
cephalosporinhydrolys
esbl
origin
clinicallyimport
carbapenemas
obscur
except
chromosom
escap
shewenella
spp
assum
carbapenemas
gene
similarli
escap
unknown
environment
organ
escap
often
entail
gene
mobilis
insert
sequenc
follow
captur
transposon
plasmid
facilit
dissemin
bla
kpc
regardless
geograph
origin
gener
carri
often
within
pkpqil
plasmid
whilst
bla
often
encod
element
carri
small
rang
plasmid
bla
differ
slightli
bla
appear
separ
escap
shewenella
associ
element
quit
differ
transposon
moreov
bla
epidemiolog
link
india
wherea
classic
bla
link
turkey
middl
east
bla
imp
bla
vim
metallocarbapenemas
occur
cassett
within
class
integron
bla
ndm
gener
link
carri
wide
divers
differ
plasmid
may
arisen
chimera
encod
first
six
amino
acid
otherwis
delet
preexist
metallocarbapenemas
gene
unknown
origin
plasmid
encod
enzym
major
metallo
type
ie
imp
ndm
vim
spread
among
strain
speci
enzym
predilect
klebsiella
pneumonia
frequent
occur
also
escherichia
coli
enterobact
enterobacteriacea
speci
individu
produc
strain
caus
local
outbreak
singl
strain
becom
nation
global
widespread
rather
produc
becam
preval
common
pattern
one
small
cluster
within
wider
epidemiolog
plasmid
transfer
among
strain
contrast
kpc
carbapenemas
carri
transposon
within
pkpqil
plasmid
strongli
associ
k
pneumonia
lineag
along
variant
eg
becom
intern
widespread
respons
major
expans
carbapenemaseproduc
enterobacteriacea
eg
greec
itali
brazil
israel
last
countri
brought
control
achiev
determin
central
mandat
infect
control
effort
kpc
problem
link
manchest
england
problem
akin
carbapenemas
type
entail
plasmid
transfer
among
strain
speci
plasmid
respons
pkpqil
variant
larg
substitut
result
replac
partit
replic
function
potenti
explain
spread
divers
carbapenemas
type
host
exacerb
problem
resist
selfevid
harder
devis
new
pharmaceut
inhibit
evad
multipl
carbapenemas
famili
develop
inhibit
evad
singl
close
relat
enzym
type
experi
suggest
harder
mobilis
infect
control
staff
effort
plasmid
epidem
carbapenemas
singl
strain
epidem
carbapenemresist
enterobacteriacea
cre
increasingli
report
worldwid
past
year
repres
seriou
threat
public
health
invas
cre
infect
associ
high
mortal
cre
potenti
spread
wide
carbapenem
resist
enterobacteriacea
mainli
result
two
differ
mechan
cre
possess
either
ampc
extendedspectrum
esbl
concomit
porin
mutat
render
organ
nonsuscept
carbapenem
importantli
cre
may
result
product
carbapenemas
break
carbapenem
carbapenemas
belong
heterogen
group
molecular
class
penicillinas
class
b
metalloenzym
class
oxacillinas
clsi
eucast
updat
carbapenem
clinic
breakpoint
enterobacteriacea
order
better
predict
treatment
outcom
provid
therapeut
altern
carbapenemresist
bacteria
breakpoint
base
patient
respons
pharmacokineticpharmacodynam
inform
vitro
minim
inhibitori
concentr
data
new
lower
breakpoint
routin
test
carbapenemas
clinic
laboratori
becam
requir
patient
care
howev
updat
breakpoint
carbapenemas
produc
cre
nonsuscept
carbapenem
use
updat
breakpoint
studi
identifi
occasion
isol
klebsiella
pneumonia
kpc
vim
carbapenemas
suscept
one
carbapenem
clinic
data
avail
support
mic
import
presenc
carbapenemas
predict
carbapenem
treatment
outcom
differ
breakpoint
imipenem
meropenem
clsi
eucast
may
need
evalu
optim
patient
care
well
epidemiolog
studi
carbapenemas
detect
character
recommend
public
health
infect
control
current
varieti
phenotyp
assay
modifi
hodg
test
carba
np
test
modifi
carbapenemas
inactiv
method
molecular
assay
none
current
describ
phenotyp
test
detect
carbapenemas
molecular
test
often
use
golden
standard
inher
limit
miss
novel
variant
andor
previous
undescrib
enzym
cre
continu
present
challeng
relat
treatment
decis
physician
detect
method
appli
laboratori
continu
effort
improv
detect
method
make
rapid
sensit
unbias
specif
carbapenemas
hope
allow
better
patient
care
prevent
cre
dissemin
ami
neuberg
md
infect
caus
carbapenemresist
enterobacteriacea
cre
difficult
treat
current
arsen
antibiot
limit
avail
antibiot
less
efficaci
rigor
studi
present
provid
brief
overview
futur
treatment
cre
infect
number
controversi
regard
mode
administr
antibot
cre
infect
high
versu
lower
dose
continu
prolong
versu
intermitt
administr
durat
antibiot
treatment
mono
versu
dual
therapi
current
evid
support
prolong
continu
administr
antibiot
new
random
control
trial
mono
versu
dual
antimicrobi
therapi
short
versu
long
durat
treatment
gramneg
bacteremia
ongo
result
expect
avail
older
antibiot
colistin
aminoglycosid
fosfomycin
tigecyclin
increasingli
use
togeth
newli
approv
drug
ceftazidimeavibactam
new
antibiot
advanc
stage
develop
phase
trial
review
drug
includ
combin
carbapenem
aztreonam
inhibitor
new
combin
cephalosporin
inhibitor
cefiderecola
novel
cephalosporin
plazomicinan
aminoglycosid
eravacyclinea
new
fluorocyclin
advantag
disadvantag
drug
discuss
novel
approach
antibiot
develop
includ
use
antibacteri
produc
previous
noncultur
bacteria
develop
new
entri
mechan
antibiot
gramneg
bacilli
treatment
cre
infect
like
undergo
rapid
chang
upcom
year
chang
accompani
comprehens
infectioncontrol
program
antibiot
stewardship
program
hospit
commun
judici
use
new
antibiot
one
health
approach
one
hdealth
one
medicin
global
recogn
control
zoonot
diseas
world
organ
anim
health
oie
report
human
pathogen
anim
origin
emerg
anim
diseas
zoonos
mean
collabor
cooper
anim
human
medicin
togeth
solv
problem
recent
huge
outbreak
highli
pathogen
avian
influenza
hpai
middl
east
respiratori
syndrom
mer
korea
pay
attent
implement
one
health
approach
practic
experienc
sever
hpai
epidem
past
ten
year
mer
bear
huge
damag
one
health
becom
key
approach
control
zoonot
diseas
system
effect
one
health
approach
minim
antimicrobi
resist
human
anim
need
collabor
among
respons
three
part
human
health
anim
health
environment
healthcommun
surveil
antimicrobi
usag
resist
provid
import
data
identif
resist
problem
contribut
factor
develop
spread
resist
nation
local
level
pain
korean
experi
zoonot
diseas
global
challeng
amr
bring
us
establish
effect
prevent
method
earli
diagnosi
critic
control
strategi
prevent
control
infect
essenti
fight
antimicrobi
resist
thu
minim
infect
anim
human
decreas
volum
antimicrobi
use
collabor
effort
implement
improv
anim
human
health
one
health
activ
nipah
bangladesh
high
risk
countri
zoonot
diseas
spillov
man
epidemiolog
investig
bangladesh
implic
consumpt
date
palm
sap
major
rout
transmiss
viru
bat
human
bangladesh
date
palm
sap
collect
date
palm
tree
consumpt
either
fresh
ferment
beverag
sap
collect
clay
pot
attach
top
portion
tree
tree
denud
bar
sap
ooz
overnight
collect
pot
outbreak
diseas
typic
occur
winter
month
interv
date
palm
sap
collect
well
casecontrol
studi
identifi
consumpt
date
palm
sap
beverag
risk
factor
individu
level
video
use
infrar
camera
document
fruit
bat
visit
date
palm
tree
night
contamin
collect
pot
lick
ooz
sap
urin
collect
pot
ethnograph
studi
affect
popul
enabl
develop
behavior
chang
intervent
reduc
consumpt
date
palm
sap
addit
bamboo
skirt
place
around
denud
bark
area
date
palm
tree
collect
pot
develop
obstruct
contamin
collect
date
palm
sap
bat
saliva
urin
great
concern
epidemiolog
studi
bangladesh
also
identifi
persontoperson
transmiss
viru
patient
person
close
contact
patient
secret
often
hospit
set
studi
nipah
outbreak
attribut
case
persontoperson
transmiss
though
patient
assess
transmit
infect
onward
via
rout
importantli
handwash
seem
effect
reduc
persontoperson
transmiss
aggreg
studi
illustr
power
multidisciplinari
collabor
rubric
one
health
view
document
persontoperson
transmiss
bangladesh
potenti
emerg
new
genet
variant
nipah
capabl
sustain
humantohuman
transmiss
underscor
need
continu
surveil
control
effort
includ
develop
effect
vaccin
mycoplasma
pneumonia
mp
one
common
caus
communityacquir
pneumonia
children
young
adult
emerg
resist
macrolid
among
mp
great
concern
sinc
macrolideresist
mp
strain
first
report
notabl
japan
china
korea
although
macrolid
recommend
firstlin
treatment
mp
pneumonia
efficaci
macrolid
treatment
pneumonia
infect
remain
unclear
addit
increas
macrolid
resist
concern
efficaci
macrolid
treatment
mp
pneumonia
children
rais
given
versatil
featur
mp
pneumonia
determin
patient
age
immunolog
respons
host
extrapulmonari
manifest
comprehens
approach
must
establish
analyz
clinic
outcom
mp
pneumonia
accord
presenc
macrolid
resist
initi
treatment
mp
pneumonia
antimicrobi
support
random
trial
marin
recruit
show
shorten
fever
durat
allevi
cough
improv
chest
xray
recent
systemat
review
evalu
effect
treat
mp
pneumonia
demonstr
signific
clinic
benefit
antimicrobi
therapi
children
mp
pneumonia
although
much
known
clinic
impact
macrolid
resist
sever
mp
pneumonia
macrolid
resist
alon
seem
explain
sever
mp
pneumonia
studi
report
patient
infect
macrolideresist
strain
febril
day
longer
durat
persist
cough
infect
macrolidesuscept
strain
suggest
poorer
respons
macrolid
treatment
macrolideresist
strain
result
highlight
need
welldesign
prospect
studi
assess
therapeut
benefit
macrolid
adjunct
therapeut
strategi
treatment
children
macrolideresist
mp
pneumonia
mayo
clinic
usa
mycoplasma
pneumonia
mp
caus
upper
lower
respiratori
tract
infect
children
adolesc
communityacquir
pneumonia
cap
compris
major
burden
diseas
mp
infect
gener
mild
selflimit
patient
age
may
develop
sever
fulmin
infect
pulmonari
complic
andor
extrapulmonari
manifest
may
affect
almost
everi
organ
present
focu
pulmonari
infect
due
mp
estim
children
mp
respiratori
infect
develop
cap
less
sever
enough
requir
hospit
although
may
chang
increas
preval
mrmp
children
mp
cap
present
longer
durat
fever
compar
children
cap
due
organ
complic
diagnosi
mp
insensit
test
organ
grow
well
cultur
inabl
perform
reliabl
sequenti
serolog
test
pcr
test
coexist
mp
pathogen
asymptomat
carriag
mp
patient
pathogen
effect
respiratori
tract
may
direct
activ
infect
indirect
infectioninduc
immun
mechan
immunopatholog
poorli
understood
particular
role
cellmedi
immun
cmi
studi
demonstr
increas
concentr
acut
phase
serum
pleural
fluid
sampl
inf
gamma
patient
mrmp
sever
cap
correl
posit
size
cutan
indur
follow
intraderm
inject
mp
antigen
postul
cytoadher
mp
respiratori
epithelium
initi
immun
respons
progress
excess
inflammatori
respons
vigor
cmi
respons
lead
pulmonari
injuri
sever
clinic
ill
macrolid
remain
drug
choic
treatment
mp
infect
children
altern
drug
tetracyclin
fluoroquinolon
first
line
due
agerel
advers
effect
macrolid
resist
pneumonia
mrmp
report
earli
japan
rate
greater
area
japan
china
korea
report
mrmp
mrmp
north
america
report
preval
approxim
europ
report
rate
israel
high
mani
countri
unreport
rate
like
due
lack
suscept
test
mechan
resist
genet
point
mutat
posit
domain
v
peptid
transferas
loop
rrna
macrolid
bind
rrna
subunit
mp
pneumonia
preval
throughout
korea
caus
sever
clinic
featur
time
led
unpublish
observ
may
associ
mrmp
despit
increas
preval
resist
macrolid
remain
drug
choic
treatment
mp
infect
children
requir
antimicrobi
stewardship
increas
clinic
sever
mp
pneumonia
grow
evid
role
overreact
host
defens
role
corticosteroid
investig
studi
healthi
patient
follow
retrospect
either
sever
pneumonia
high
fever
respiratori
distress
initi
lobar
pneumon
consolid
without
pleural
effus
refractori
pneumonia
prolong
fever
day
persist
consolid
one
lobe
lung
despit
appropri
antimicrobi
therapi
diagnos
serolog
viral
coinfect
receiv
appropri
antimicrobi
macrolid
betalactam
methylprednisolon
mgkgday
day
improv
although
mrmp
may
caus
sever
refractori
mp
suscept
test
perform
studi
often
mp
caus
benign
respiratori
ill
may
involv
upper
lower
respiratori
tract
mp
potenti
caus
sever
diseas
emerg
mrmp
led
sever
mp
pneumonia
macrolid
resist
one
potenti
caus
sever
diseas
exuber
host
inflammatori
respons
releas
cytokin
perhap
mediat
larg
cmi
appear
play
role
children
adolesc
latter
situat
corticosteroid
may
prove
benefici
research
need
done
last
three
decad
mani
studi
investig
best
approach
promot
hand
hygien
practic
improv
hand
hygien
indic
particular
healthcar
worker
hcw
complianc
earli
studi
hand
hygien
improv
healthcar
focus
singl
intervent
promot
import
handwash
introduc
use
antimicrobi
soap
group
geneva
conduct
first
largescal
epidemiolog
research
hand
hygien
identifi
major
risk
factor
noncompli
demonstr
critic
role
alcoholbas
handrub
abhr
major
system
chang
replac
handwash
soap
water
includ
multimod
strategi
chang
hcw
behavior
strategi
combin
easi
access
abhr
proven
bypass
time
constraint
hcw
hcw
educ
perform
monitor
feedback
remind
workplac
institut
safeti
climat
strategi
referenc
geneva
model
hand
hygien
promot
proven
success
hand
hygien
improv
associ
signific
reduct
healthcareassoci
infect
hai
spread
multiresist
organ
geneva
model
hand
hygien
promot
replic
singl
well
multipl
healthcar
institut
local
region
nation
level
success
sinc
world
health
organ
mandat
group
lead
first
global
patient
safeti
challeng
clean
care
safer
care
main
object
rais
awar
hai
worldwid
mobil
nation
toward
ipc
activ
promot
best
ipc
practic
particular
hand
hygien
recent
metaanalysi
luangasanatip
et
al
demonstr
critic
role
multimod
approach
success
hand
hygien
promot
nevertheless
sever
knowledg
gap
hand
hygien
monitor
efficaci
remain
lectur
focu
follow
topic
area
relat
key
question
hand
hygien
research
agenda
studi
direct
indirect
monitor
hand
hygien
complianc
includ
new
devic
observ
feedback
studi
influenc
handrub
durat
ii
volum
abhr
use
iii
optim
sequenc
handrub
step
within
handrub
techniqu
reduct
bacteri
count
hcw
hand
studi
burden
diseas
implement
infect
prevent
control
strategi
worldwid
studi
possibl
role
patient
particip
empower
hand
hygien
promot
hepat
c
viru
hcv
infect
one
common
chronic
liver
diseas
global
estim
million
peopl
hcv
antibodi
preval
patient
infect
hcv
acquir
diseas
intraven
drug
use
blood
transfus
latter
becom
rare
sinc
routin
test
blood
suppli
hcv
began
nosocomi
transmiss
hcv
document
sever
health
care
set
stringent
infect
control
protocol
prevent
transmiss
particularli
unsaf
medic
inject
practic
nosocomi
transmiss
still
report
gener
breach
protocol
rare
sourc
transmiss
hcv
includ
contamin
equip
use
perform
procedur
breakdown
infect
control
procedur
asept
techniqu
lead
persontoperson
transmiss
screen
hepat
c
viru
hcv
infect
import
compon
success
control
hcv
infect
individu
public
health
purpos
diagnost
test
hepat
c
viru
hcv
serolog
assay
detect
antibodi
hepat
c
molecular
assay
detect
quantifi
hcv
rna
investig
genotyp
test
serum
fibrosi
panel
liver
biopsi
may
help
predict
respons
treatment
prognosi
case
acut
hcv
infect
anicter
asymptomat
fewer
clinic
appar
fulmin
hepat
c
rare
go
chronic
infect
substanti
proport
develop
cirrhosi
subset
develop
hepatocellular
carcinoma
activ
surveil
base
mdr
gramneg
pathogen
anucha
apisarnthanarak
md
activ
surveil
one
common
strategi
employ
control
mdrgram
neg
pathogen
although
list
guidelin
true
valu
activ
surveil
mdr
gramneg
pathogen
never
demonstr
sever
consider
made
infect
preventionist
implement
activ
surveil
part
control
measur
includ
specif
reservoir
specif
mdr
gramneg
pathogen
resourc
avail
isol
precaut
turnaround
time
activ
surveil
cultur
whether
institut
abl
implement
infect
prevent
strategi
togeth
activ
surveil
cultur
session
address
proand
confor
activ
surveil
cultur
mdr
gramneg
pathogen
applic
activ
surveil
cultur
resourcelimit
set
also
discuss
also
rate
cathet
associ
urinari
tract
infect
cauti
cline
associ
blood
stream
infect
clbsi
significantli
decreas
per
catheterday
f
p
per
catheterday
f
p
subgroup
analysi
rate
vap
cauti
clbsi
significantli
decreas
regardless
organiz
institut
characterist
icu
summari
dahai
shown
signific
reduct
last
year
howev
vur
yearwis
significantli
increas
trend
past
also
ucur
clur
decreas
trend
significantli
need
effort
make
reduct
devic
util
ratio
associ
infect
invas
fungal
infect
ifi
primari
caus
mortal
rapid
accur
diagnost
laboratori
test
requir
improv
patient
outcom
although
histopatholog
examin
tissu
detect
ifi
tissu
morpholog
alon
insuffici
distinguish
aspergillu
fungi
includ
fusarium
scedosporium
mucoral
therefor
speci
identif
use
cultur
noncultur
method
necessari
recent
assay
target
ribosom
dna
use
identifi
infecti
fungi
tissu
notabl
analys
use
frozen
tissu
superior
use
formalinfix
paraffinembed
tissu
panfung
primer
hybrid
dna
eukaryot
panfung
approach
limit
tissu
primarili
contain
human
dna
littl
fungal
dna
diagnost
test
reli
fungal
cultur
common
ifi
recent
howev
dna
sequenc
matrixassist
laser
desorpt
ioniz
timeoffight
mass
spectrometri
malditof
ms
use
rapidli
accur
identifi
fungal
pathogen
recov
cultur
sequencebas
identif
particularli
use
identifi
cryptic
speci
misidentifi
microscop
analys
identifi
complex
level
cryptic
speci
resist
azol
antifung
agent
molecular
method
develop
detect
azoleand
echinocandinresist
candida
speci
well
azoleresist
aspergillu
speci
blood
cultur
gold
standard
diagnos
candidemia
howev
cultur
requir
day
growth
follow
addit
day
identif
antifung
suscept
test
timefram
lead
delay
treatment
initi
addit
onethird
patient
invas
candidiasi
fail
test
posit
blood
cultur
pcr
bdg
assay
sensit
blood
cultur
patient
deepseat
candidiasi
bdg
cell
wall
compon
candida
fungal
speci
except
mucoral
cryptococcu
includ
eorticmsg
revis
diagnost
criteria
invas
fungal
diseas
howev
bdg
assay
expens
laborintens
make
unavail
develop
countri
bdg
assay
highli
sensit
lack
specif
thu
typic
suitabl
rule
caus
candidiasi
serum
galactomannan
gm
cell
wall
compon
aspergillu
detect
serum
use
commerci
test
aspergillu
eia
biorad
usa
serum
gm
test
consid
aspergillusspecif
multipl
studi
demonstr
high
sensit
sera
patient
hematolog
malign
allogen
hematopoiet
stem
cell
transplant
howev
gm
sensit
low
nonneutropen
patient
recipi
solid
organ
transplant
addit
gm
test
associ
poor
predict
valu
patient
receiv
moldact
antifung
prophylaxi
howev
detect
gm
bal
fluid
high
even
among
patient
receiv
moldact
antifung
therapi
multipl
studi
shown
pcr
sensit
cultur
method
detect
aspergillu
blood
respiratori
fluid
multipl
pcr
assay
commerci
avail
detect
aspergillu
spp
howev
none
fdaapprov
moreov
aspergillusspecif
pcr
recommend
clinic
use
assay
standard
valid
assay
biosystem
usa
recent
introduc
detect
five
common
candida
speci
wholeblood
sampl
assay
fdaapprov
diagnost
test
offer
rapid
diagnosi
hour
specif
organ
identif
detect
limit
cfuml
develop
addit
diagnost
test
facilit
earli
diagnosi
manag
ifi
highrisk
patient
newest
treatment
strategi
candidemia
thoma
f
patterson
professor
medicin
ut
health
san
antonio
san
antonio
texa
usa
candidemia
import
caus
morbid
mortal
especi
hospit
immunocompromis
patient
despit
advanc
antifung
therapi
number
antifung
drug
drug
class
treat
seriou
infecti
remain
limit
manag
complic
fact
remain
difficult
establish
accur
diagnosi
compound
need
earli
therapi
fluconazol
remain
use
antifung
agent
especi
followon
therapi
stabil
infect
resist
high
speci
includ
c
glabrata
thu
echinocandin
becom
recommend
primari
therapi
patient
howev
develop
echinocandin
drug
resist
strain
report
worldwid
develop
drug
resist
often
tie
antifung
drug
use
particularli
speci
like
candida
glabrata
multidrug
resist
uncommon
increas
report
multidrug
resist
azol
echinocandin
polyen
occur
sever
candida
speci
notabl
candida
glabrata
recent
candida
auri
new
agent
develop
candidemia
includ
echinocandin
improv
pharmacokinet
profil
avail
oral
use
addit
agent
new
target
action
also
undergo
preclin
develop
diagnosi
infect
detect
antifung
resist
critic
success
manag
patient
infect
new
therapi
aim
improv
outcom
candidemia
epidemiolog
manag
mucormycosi
invas
aspergillosi
lesson
learn
centr
infecti
diseas
microbiolog
laboratori
servic
icpmr
westmead
hospit
univers
sydney
new
south
wale
australia
epidemiolog
aspergillu
mucoral
infect
may
chang
although
invas
aspergillosi
ia
remain
substant
caus
morbid
patient
neutropenia
hematolog
malign
organ
transplant
expans
spectrum
risk
patient
patient
intens
care
unit
icu
chronic
lung
diseas
hivaid
immunomodul
drug
amongst
rel
understudi
popul
diagnost
difficulti
includ
interpret
aspergillu
cultur
contribut
limit
expans
host
risk
group
shift
etiolog
ia
cryptic
uncommon
speci
emerg
addit
azoleresist
fumigatu
infect
pose
increas
dilemma
region
europ
asia
resist
rate
gener
voriconazol
recommend
primari
treatment
ia
regardless
site
infect
azol
echinocandin
amphotericin
b
compound
may
use
second
line
salvag
therapi
primari
combin
therapi
routin
advis
surgic
derbrid
resect
import
adjunct
feasibl
presenc
azol
resist
either
liposom
amphotericin
b
lamb
voriconazoleechinocandin
combin
prefer
vitro
suscept
test
recommend
ia
case
isavuconazol
good
activ
aspergillu
new
antifung
drug
antiaspergillu
activ
develop
mani
case
mucormycosi
affect
host
malign
stem
cell
transplant
organ
transplant
diabet
mellitu
iron
overload
also
import
underli
condit
although
use
certain
calcineurin
inhibitor
may
associ
lower
risk
emerg
risk
includ
underli
rheumatologicalautoimmun
condit
traumarel
case
may
also
increas
outbreak
infect
follow
natur
disast
iatrogen
exposur
describ
pathogen
epidemiolog
vari
region
emerg
uncommon
genera
apophysomyc
despit
best
practic
manag
revers
risk
mortal
treatment
base
case
seri
expert
opinion
surgic
debridementresect
combin
antifung
improv
outcom
initi
treatment
lamb
prefer
agent
although
optim
dosag
uncertain
isavuconazol
appear
efficaci
lamb
combin
polyeneechinocandin
consid
extens
diseas
salvag
therapi
posaconazol
typic
employ
stepdown
therapi
treatment
algorithm
may
chang
wider
avail
iv
posaconazol
new
drug
pipelin
endem
fungal
infect
asiapacif
region
context
alter
immun
nation
univers
health
system
singapor
less
known
incid
character
deep
mycos
asia
pacif
region
geoclimat
condit
popul
demograph
health
resourc
access
vari
within
respect
asian
countri
also
differ
west
invas
fungal
diseas
ifd
encount
region
discuss
specif
highlight
uniqu
challeng
face
pertain
host
immun
suscept
manag
diseas
candidemia
candidiasi
constitut
highest
proport
ifd
particular
contribut
candida
tropicali
tropic
asia
pacif
overlook
candida
tropicali
infect
link
sever
diseas
seen
patient
weaken
immun
hematolog
malign
neonat
host
immun
factor
recent
identifi
predispos
oroesophag
candidiasi
also
discuss
chronic
cavitatori
pulmonari
aspergillosi
cpa
asia
often
sequela
old
tuberculosi
well
aspergillosi
critic
ill
underrecogn
immun
interplay
ubiquit
mold
host
defens
sever
ill
explor
cryptococcosi
penicilliosi
tradit
seen
patient
infect
human
immunodefici
viru
hiv
cryptococcu
infect
recogn
occur
beyond
context
hiv
even
appar
immunocompet
subject
recent
immun
suscept
patient
cryptococcu
dissect
similarli
notabl
predilect
talaormyc
marneffei
rare
fungi
asia
pacif
region
link
nonhivattribut
host
immun
defect
includ
novel
diseas
trait
seemingli
distinct
asian
preexposur
prophylaxi
scienc
implement
rossana
ditangco
md
prep
hiv
refer
prevent
strategi
take
medic
agent
prior
hiv
exposur
method
specif
involv
oral
intak
antiretrovir
drug
arv
hivneg
individu
high
risk
acquir
viru
order
prevent
hiv
infect
recent
studi
demonstr
safeti
efficaci
dual
antiretrovir
arv
oral
preexposur
prophylaxi
prep
prevent
sexual
parenter
transmiss
hiv
infect
iprex
studi
random
control
efficaci
trial
men
sex
men
msm
small
conting
maletofemal
transgend
women
tgw
particularli
relev
asia
pacif
studi
emticitrabinetenofovir
disoproxil
fumar
ftctdf
truvada
safe
achiev
perprotocol
reduct
new
hiv
infect
howev
risk
reduct
ftctdf
recipi
detect
studydrug
blood
level
indic
much
greater
efficaci
associ
increas
adher
subsequ
pharmacolog
model
followup
studi
demonstr
daili
use
agent
requir
achiev
optim
protect
declin
gradual
scale
associ
decreas
frequenc
use
research
show
reduct
hiv
infect
risk
dose
dose
dose
ftctdf
per
week
protect
efficaci
nondaili
dose
risk
reduct
subsequ
confirm
placebocontrol
trial
intermitt
ondemand
ftctdf
prep
among
msm
franc
canada
mathemat
model
use
iprex
find
demonstr
substanti
reduct
new
hiv
infect
associ
modest
prep
program
coverag
msm
increas
prep
adher
shown
largest
popul
level
prevent
impact
greatest
costeffect
prep
implement
shown
feasibl
openlabel
extens
project
site
research
program
capac
despit
excel
safeti
efficaci
profil
proof
implement
prep
resourcelimit
set
outsid
situat
still
need
deliv
applic
prep
resourc
limit
situat
must
ground
realiti
exist
health
system
interfac
communitylevel
primari
care
clinicand
hospitalbas
servic
number
unknown
remain
respect
deliveri
hiv
prep
msmtgw
environ
among
other
access
uptak
adher
effect
behavior
social
impact
effect
describ
take
part
prep
project
use
arv
drug
may
disclos
samesex
behavior
hiv
risk
turn
may
provok
neg
reaction
undu
pressur
social
profession
famili
environ
particip
may
see
certain
servic
privileg
revok
deni
worst
case
scenario
disclosur
may
lead
denial
termin
health
lifeinsur
rental
agreement
employ
promot
neg
repercuss
constitut
violat
individu
right
may
advers
impact
project
particip
prep
access
uptak
adher
particular
concern
poor
adher
increas
sexual
risk
behavior
latter
potenti
acceler
sexual
transmit
infect
sti
follow
increas
hiv
acquisit
transmiss
nonprep
servic
portion
risk
popul
present
countri
vari
stage
introduc
daili
oral
prep
use
tdfftc
recommend
option
peopl
substanti
risk
hiv
countri
nation
program
other
smallerscal
program
other
nt
offer
prep
benefit
prep
prevent
strategi
goe
beyond
clinic
efficaci
prep
program
could
increas
hiv
test
uptak
contact
health
care
provid
hiv
counsel
educ
servic
earli
diagnosi
treatment
sexual
transmit
infect
scientif
evid
efficaci
safeti
prep
mathemat
model
cost
effect
potenti
elimin
new
hiv
infect
project
benefit
beyond
clinic
effect
provid
rational
make
prep
avail
addit
layer
hiv
prevent
strategi
center
aid
research
kumamoto
univers
kumamoto
japan
despit
signific
reduct
morbid
mortal
follow
combin
antiretrovir
therapi
art
emerg
evid
peopl
success
treat
hiv
infect
art
age
prematur
lead
progress
multiorgan
diseas
refer
comorbid
one
major
factor
involv
pathogen
process
residu
viral
replic
persist
infect
cell
surviv
vivo
subsequ
chronic
inflamm
contrast
current
art
target
viral
replic
neutral
nonneutr
antibodi
envelop
protein
report
adcc
antibodymedi
cellular
cytotox
activ
elimin
infect
cell
vitro
discoveri
potent
broadli
neutral
antibodi
bnab
hiv
made
passiv
immun
potenti
strategi
prevent
treatment
hiv
infect
bnab
target
hiv
site
test
treatment
patient
treatment
patient
delay
plasma
viral
rebound
discontinu
art
monoclon
antibodi
target
glycan
supersit
use
highest
dose
mgkg
show
rapid
declin
viremia
howev
virolog
analys
reveal
emerg
multipl
independ
neutral
resist
mutant
everi
case
conduct
phase
clinic
trial
passiv
transfer
neutral
monoclon
antibodi
reactiv
tip
region
elig
subject
random
receiv
one
dose
treatment
found
safe
well
toler
observ
signific
decreas
hivrna
mgkg
cohort
two
six
case
achiev
log
reduct
hivrna
longterm
suppress
viral
load
observ
one
patient
despit
signific
decreas
plasma
concentr
suggest
effect
antibodi
neutral
previous
report
neutral
escap
mutant
becam
sensit
chemokin
cc
receptor
ccr
inhibitor
maraviroc
cenicriviroc
convers
resist
mutant
inhibitor
becam
sensit
sever
neutral
antibodi
includ
furthermor
seri
vitro
experi
suggest
synergist
effect
combin
antagonist
includ
maraviroc
figur
result
taken
togeth
suggest
combin
neutral
antibodi
would
promis
candid
intensif
therapi
ad
onto
current
suppress
art
aim
toward
function
cure
diseas
programm
nucleasesinclud
zincfing
nucleas
zfn
transcript
activatorlik
effector
nucleas
talen
rnaguid
engin
nucleas
rgen
deriv
bacteri
cluster
regularli
interspac
short
palindrom
repeat
crispr
ca
crisprassoci
systemen
target
genet
modif
cultur
cell
well
whole
anim
plant
valu
enzym
research
medicin
biotechnolog
aris
abil
induc
sitespecif
dna
cleavag
genom
repair
endogen
mechan
allow
highprecis
genom
edit
howev
nucleas
differ
sever
respect
includ
composit
target
site
specif
mutat
signatur
among
characterist
knowledg
nucleasespecif
featur
well
pro
con
essenti
research
choos
appropri
tool
rang
applic
group
recent
report
effector
endonucleas
protein
class
crisprca
system
sever
differ
cleavag
overhang
shorter
guid
rna
longer
distanc
seed
sequenc
cleavag
site
could
provid
potenti
advantag
case
genom
edit
nonhomolog
end
joiningbas
gene
insert
effici
genom
edit
use
homologydirect
repair
howev
limit
inform
avail
activ
profil
mammalian
cell
preclud
wide
use
genom
edit
furthermor
select
highli
effici
guid
rna
collect
big
data
determin
paramet
rnaprogramm
nucleas
current
labori
costli
due
lack
reliabl
highthroughput
approach
determin
rnaprogramm
nucleas
activ
mammalian
cell
perform
en
mass
evalu
guid
rna
activ
use
synthet
target
sequenc
deep
sequenc
use
vivo
highthroughput
approach
determin
onand
offtarget
activ
profil
protospac
adjac
motif
pam
sequenc
found
sequenc
featur
high
activ
guid
rna
distinct
pam
mammalian
cell
tttv
rather
tttn
previous
determin
use
vitro
system
evalu
offtarget
activ
show
target
sequenc
divid
three
region
base
pair
bp
seed
bp
trunk
bp
promiscu
region
result
serv
use
guid
select
genom
edit
tool
importantli
vivo
highthroughput
evalu
system
greatli
facilit
select
effici
precis
guid
rna
gener
big
data
develop
advanc
predict
program
onand
offtarget
activ
tasp
work
infect
person
know
hisher
hiv
statu
diagnosi
made
earli
possibl
treatment
offer
promptli
time
gap
infect
viral
suppress
narrow
around
world
late
diagnosi
still
common
earli
diagnosi
often
hing
easi
access
voluntari
test
freedom
stigma
also
avail
screen
selftest
submiss
specimen
urin
saliva
dri
blood
spot
laboratori
test
solut
albeit
exist
technic
problem
need
establish
linkag
care
period
test
campaign
could
impact
hiv
epidemiolog
illustr
model
studi
parametr
hong
kong
surveil
data
patient
enrol
treatment
program
optim
regimen
crucial
ensur
lifelong
mainten
haart
without
advers
reaction
develop
world
integras
inhibitor
use
firstlin
regimen
capac
reduc
viral
load
undetect
rang
within
week
access
singl
tablet
regimen
howev
limit
place
hiv
patient
antiretrovir
exampl
abacavir
efavirenz
knowledg
host
genotyp
respect
could
minim
occurr
advers
reaction
might
otherwis
compromis
adher
notabl
adher
key
lifelong
mainten
viru
suppress
simpl
solut
guarante
adher
year
ten
year
wherea
effort
could
made
promot
test
improv
treatment
coverag
underdiagnos
interv
often
achil
heel
except
small
number
case
present
acut
infect
seroconvers
time
often
unknown
use
modifi
back
calcul
method
estim
seroconvers
year
patient
hong
kong
found
interquartil
rang
underdiagnos
interv
year
rang
year
length
undiagnos
interv
associ
age
rout
hiv
transmiss
obvious
peopl
low
perceiv
risk
hiv
infect
longer
undiagnos
interv
like
late
diagnosi
mathemat
model
increas
undiagnos
interv
would
offset
infect
avert
tasp
even
good
coverag
high
adher
assum
appar
tasp
necessari
yet
insuffici
intervent
achiev
hiv
elimin
tasp
target
peopl
infect
hiv
wherea
intervent
noninfect
individu
would
contribut
reduct
size
popul
requir
tasp
one
good
exampl
latter
preexposur
prophylaxi
access
hand
peopl
risk
around
world
effect
protocol
need
risk
compens
new
concern
let
forget
promot
protect
sex
provis
methadon
mainten
harm
reduct
measur
inject
drug
user
communitylevel
behavior
intervent
continu
power
compon
armamentarium
measur
combat
hiv
complement
tasp
achiev
hiv
elimin
stephan
harbarth
health
careassoci
infect
hcai
major
global
issu
patient
safeti
affect
hundr
million
peopl
worldwid
complic
deliveri
patient
care
contribut
patient
death
disabl
promot
resist
antibiot
gener
addit
expenditur
alreadi
incur
patient
underli
diseas
inde
hcai
grow
intern
problem
patient
becom
suscept
infect
seriou
underli
ill
poor
complianc
hand
hygien
health
care
staff
increas
recours
invas
medic
devic
care
critic
ill
well
lack
access
safe
water
unclean
instrument
environment
surfac
play
role
environ
patient
care
also
import
factor
understaf
high
bed
occup
increas
patient
transfer
creat
new
risk
infect
first
global
patient
safeti
challeng
creat
worldwid
focu
reduc
hcai
vital
element
safeti
patient
care
last
two
year
provid
import
clinic
relev
research
data
prevent
hcai
differ
patient
popul
present
summaris
result
clinic
trial
systemat
review
reduct
variou
type
hcai
discuss
context
current
relev
scientif
clinic
background
particular
discuss
recent
data
epidemiolog
prevent
nosocomi
infect
intens
care
unit
present
new
approach
prevent
surgic
site
infect
well
catheterrel
bloodstream
infect
describ
recent
advanc
hand
hygien
research
attempt
briefli
summaris
specif
challeng
relat
manag
infect
caus
multidrugresist
microorgan
overal
hcai
remain
one
key
challeng
hospit
care
significantli
contribut
morbid
mortal
paper
publish
last
year
remind
us
reduct
hcai
rate
possibleoften
help
simpl
rather
inexpens
intervent
rapid
accur
diagnosi
critic
effect
treatment
life
threaten
infect
bloodstream
respiratori
tract
complic
urinari
tract
infect
uti
clinic
syndrom
difficult
diagnos
due
complex
aetiolog
challeng
clinic
sampl
type
eg
blood
sputum
current
cultur
base
diagnosi
often
suboptim
specif
sensit
slow
impact
patient
manag
shotgun
metagenom
sequenc
potenti
chang
way
diagnos
infect
combin
rapid
comprehens
beyond
current
method
realtim
nanopor
sequenc
technolog
provid
rapid
turnaround
necessari
infecti
diseas
diagnost
applic
pointofcar
challeng
appli
sequenc
infect
diagnosi
howev
includ
high
human
pathogen
nucleic
acid
ratio
low
pathogen
number
low
qualiti
nucleic
acid
depend
diseas
clinic
sampl
type
therefor
vital
care
design
develop
optimis
diagnost
pipelin
attempt
appli
clinic
sampl
describ
develop
minion
base
infecti
diseas
diagnost
pipelin
exampl
ongo
research
pneumonia
sepsi
uti
protein
synthesi
enzym
primari
defens
system
infect
aminoacyltrna
synthetas
arss
essenti
protein
synthesi
enzym
make
coval
linkag
cognat
amino
acid
trna
sinc
catalyt
activ
arss
alway
requir
viabil
organ
constitut
express
ubiquit
present
due
featur
arss
first
expos
broad
spectrum
stress
challeng
fact
shown
divers
role
rapid
respond
signal
mediat
beyond
protein
synthesi
show
recent
find
arss
primari
defens
system
bacteri
viral
infect
instanc
tryptophanyltrna
synthetas
wr
rapidli
secret
monocyt
upon
bacteri
infect
prime
innat
immun
respons
secret
far
rapid
induct
innat
immun
system
anoth
case
glutamylprolyltrna
synthetas
epr
play
uniqu
role
viral
clearanc
epr
block
ubiquitin
mav
mitochondri
antivir
signal
protein
lead
inhibit
viral
replic
base
find
arss
expect
play
uniqu
role
infect
therebi
collect
serv
primari
shield
system
victor
lim
intern
medic
univers
kuala
lumpur
malaysia
world
face
crisi
antimicrobi
resist
amr
project
noth
done
million
peopl
die
antimicrobialresist
infect
annual
econom
cost
also
correspondingli
high
one
hundr
trillion
us
dollar
overus
antimicrobi
agent
major
driver
emerg
resist
improv
antibiot
stewardship
therefor
crucial
meet
challeng
pose
amr
would
requir
recognit
problem
stakehold
level
polit
solv
adequ
plan
provis
resourc
includ
legisl
essenti
importantli
howev
would
requir
behaviour
chang
among
stakehold
increas
recognit
provid
evid
health
research
necessari
insuffici
deliveri
optim
health
care
need
translat
knowledg
action
field
knowledg
translat
kt
scientif
studi
method
close
knowledgetopractic
gap
barrier
facilit
inher
process
method
must
employ
enjoy
success
antibiot
stewardship
esrc
work
group
amr
report
state
although
amr
involv
biolog
process
context
determin
oper
biolog
mechan
shape
social
cultur
polit
econom
process
behaviour
scienc
multidisciplinari
studi
human
anim
behavior
encompass
disciplin
psycholog
anthropolog
sociolog
econom
contribut
behaviour
scienc
improv
antibiot
stewardship
crucial
recogn
late
antibiot
prescrib
complex
behaviour
carri
inform
individu
often
make
subject
ration
choic
recent
report
depart
health
public
health
england
summaris
evid
behaviour
chang
antibiot
prescrib
healthcar
set
point
lack
underpin
psycholog
theori
behaviour
scienc
studi
done
far
result
intervent
may
effect
chang
behavior
chang
behavior
need
understand
driver
behavior
driver
prescrib
behavior
may
intrins
extrins
intrins
factor
includ
altruist
motiv
one
best
patient
ignor
durat
practic
tendenc
yield
patient
demand
fear
progress
diseas
lose
patient
lack
understand
resist
problem
extrins
factor
would
includ
patient
demand
influenc
pharmaceut
industri
diagnost
uncertainti
patient
comorbid
social
class
workload
time
pressur
role
model
senior
colleagu
financi
incent
intervent
improv
antibiot
stewardship
includ
prescrib
educ
train
issuanc
antibiot
guidelin
use
electron
decis
support
system
audit
feedback
rapid
near
patient
test
reduc
diagnost
uncertainti
restrict
strategi
pharmaci
laboratori
well
financi
strategi
increas
awar
problem
amr
among
public
social
market
strategi
employ
includ
use
mass
media
although
varieti
intervent
employ
last
decad
overal
effect
subject
question
result
variabl
work
one
set
may
work
anoth
behavior
chang
complex
process
influenc
social
econom
ethnic
cultur
belief
mani
studi
crosssect
natur
sustain
intervent
measur
design
strategi
intervent
need
understand
prescrib
patientpubl
behavior
factor
drive
use
methodolog
establish
behaviour
scienc
intervent
specif
local
context
target
popul
combin
strategi
may
necessari
modifi
behavior
desir
outcom
depart
infecti
diseas
institut
infecti
diseas
epidemiolog
tan
tock
seng
hospit
singapor
antimicrobi
resist
hospit
character
widespread
dissemin
multidrugresist
extens
drug
resist
bacteria
includ
methicillinresist
staphylococcu
aureu
vancomycinresist
enterococci
extendedspectrum
betalactamas
carbapenemas
produc
enterobacteriacea
pandrugresist
acinetobact
baumannii
combin
enhanc
infect
control
antimicrobi
stewardship
often
recommend
combat
antimicrobi
resist
hospit
multipl
strategi
recommend
profession
societi
antimicrobi
stewardship
differ
level
evid
effect
sever
recent
well
conduct
systemat
review
metaanalys
shown
antimicrobi
stewardship
effect
reduc
broadspectrum
antibiot
use
antimicrobi
resist
without
increas
advers
clinic
outcom
restrict
strategi
produc
immedi
effect
persuas
strategi
associ
sustain
impact
addit
commonli
adopt
strategi
preauthor
prospect
review
feedback
greater
varieti
antimicrobi
stewardship
intervent
recommend
particular
evidencebas
clinic
care
path
common
infect
associ
improv
mortal
howev
antimicrobi
use
hospit
part
greater
context
antimicrobi
use
resist
within
one
health
continuum
increasingli
nation
region
antimicrobi
stewardship
effort
must
move
outsid
hospit
